All In Biotech

Drug Trial Radar · NCT03948035

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd Prior to and Following Auto-SCT in Newly Diagnosed Multipe Myeloma and Subsequent Maintenance With Elotuzumab and Lenalidomide Versus Single-Agent Lenalidomide- A Phase III Study by DSMM

Last checked: Nov 20, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 576 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

576

Planned (sponsor's estimate)

Start

Aug 28, 2018

Primary completion

Aug 2029

Study completion Aug 2029

Sponsor

Lead sponsor
Wuerzburg University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ClinAssess GmbH; Arbeitsgemeinschaft medikamentoese Tumortherapie
First posted
May 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients. One phase III trial in MM patients with one to three prior lines of therapy compared elotuzumab-Rd with standard Rd. The triple combination was shown to significantly prolong PFS in this patient cohort with a greater proportion of patients in at least very good partial response (VGPR) when compared to subjects on Rd. Notably, the rate of infusion-related reactions with this specific moAb was very low, with an overall rate of 10% in premedicated patients and only 1% of Grade 3 severity. Grades 4/5 infusion-related reactions were absent and only 1% of patients on elotuzumab discontinued for infusion-related reactions. Of particular interest is the observation in this trial, that response and PFS were independent of cytogenetic high-risk features, i.e., deletion of chromosome 17p and translocation t(4;14). This effect distinguishes elotuzumab from most, if not all, other drug-based approaches. The investigators assume that incorporating the moAb into the KRd triple induction regimen should result in an even higher rate of deep (negative for MRD in conjunction with at least very good partial response \[VGPR\] as defined by the International Myeloma Working Group \[IMWG\]) with these responses occurring independently of cytogenetic risk. Due to potential interference of elotuzumab with serum immune fixation, the investigators chose VGPR rather than complete response (CR) to exclude false-positive immunofixation results. Furthermore the investigators hypothesize that combining elotuzumab with lenalidomide should prolong PFS further.

Conditions

  • Newly Diagnosed Multiple Myeloma

Interventions

  • ElotuzumabDrug

    i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.

  • CarfilzomibDrug

    i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.

  • LenalidomideDrug

    hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.

  • DexamethasoneDrug

    orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .

  • autologous stem cell transplantOther

    autologous stem cell transplant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Induction phaseTime frame: At the end of Cycle 6 (168 days for all cycles plus up to 36 days)
  2. Maintenance phaseTime frame: 3 years from randomisation

Locations

56 sites in 2 countries. Site status is shown where the registry gives one.

  • Landeskrankenhaus Salzburg

    Salzburg, Austria

  • AKH Meduni Wien

    Vienna, Austria

  • Klinik Ottakring

    Vienna, Austria

  • Univ. Klinikum Krems

    Krems, Lower Austria, Austria

  • Universitätklinikum St. Pölten

    Sankt Pölten, Lower Austria, Austria

  • LKH-Universitätsklinikum Graz

    Graz, Styria, Austria

  • Medizinische Universität Innsbruck

    Innsbruck, Tyrol, Austria

  • Kepler Universitätsklinikum

    Linz, Upper Austria, Austria

  • Klinikum Wels-Grieskirchen

    Wels, Upper Austria, Austria

  • LKH Rankweil-Feldkirch

    Rankweil, Vorarlberg, Austria

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Helios Kliniken

    Berlin, Germany

  • Vivantes Klinikum Spandau

    Berlin, Germany

  • Klinikum Bremen-Mitte

    Bremen, Germany

  • Asklepios Klinik Altona

    Hamburg, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Kliniken Ostalb

    Mutlangen, Baden-Wurttemberg, Germany

  • Studienzentrum Onkologie Ravensburg

    Ravensburg, Baden-Wurttemberg, Germany

  • Diakonieklinikum Stuttgart

    Stuttgart, Baden-Wurttemberg, Germany

  • Robert-Bosch Krankenhaus

    Stuttgart, Baden-Wurttemberg, Germany

  • Universitätsklinikum Ulm

    Ulm, Baden-Wurttemberg, Germany

  • Onkologie Schwarzwald-Alb

    Villingen-Schwenningen, Baden-Wurttemberg, Germany

  • Gesundgheitszentrum St. Marien

    Amberg, Bavaria, Germany

  • Klinikum Augsburg

    Augsburg, Bavaria, Germany

  • Sozialstiftung Bamberg

    Bamberg, Bavaria, Germany

  • Klinikum Bayreuth

    Bayreuth, Bavaria, Germany

  • Klinikum Kempten-Oberallgäu

    Kempten (Allgäu), Bavaria, Germany

  • Rotkreuzklinikum München

    Munich, Bavaria, Germany

  • Ludwig-Maximilians-Universität München

    Munich, Bavaria, Germany

  • Klinikum rechts der Isar der TU München

    Munich, Bavaria, Germany

  • Klinikum Nürnberg Nord

    Nuremberg, Bavaria, Germany

  • Uniklinikum Regensburg

    Regensburg, Bavaria, Germany

  • Klinikum Traunstein

    Traunstein, Bavaria, Germany

  • Universitätsklinikum Würzburg, Medizinische Klinik II

    Würzburg, Bavaria, Germany

  • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main

    Frankfurt am Main, Hesse, Germany

  • Universitätsklinikum Göttingen

    Göttingen, Lower Saxony, Germany

  • Med. Hochschule Hannover

    Hanover, Lower Saxony, Germany

  • Klinikum Oldenburg

    Oldenburg, Lower Saxony, Germany

  • Universitätmedizin Greifswald

    Greifswald, Mecklenburg-Pomerania, Germany

  • Universitätsmedizin Rostock

    Rostock, Mecklenburg-Pomerania, Germany

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.